{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-017478","form_type":"8-K","ticker":null,"cik":"0001106838","company_name":"Sonnet BioTherapeutics Holdings, Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.353047+00:00","generated_at":"2026-05-18T09:34:48.062728+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sonnet BioTherapeutics raises $2.0M via zero-interest convertible notes and warrants; conversion at $1.156/share","bullets":["Completed sale of $2.0M aggregate principal convertible notes to accredited investors, plus ~$50,000 from warrants.","Convertible notes bear no interest, mature June 30, 2026; convertible into up to 1,730,104 shares at $1.156 per share.","Warrants to purchase 865,052 shares at $1.156 per share, exercisable for five years.","If no subsequent offering of $5M+ within 90 days, investors can buy additional warrants and company must file registration statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-017478","json":"https://secwatch.observer/filing/0001641172-25-017478.json","markdown":"https://secwatch.observer/filing/0001641172-25-017478.md","text":"https://secwatch.observer/filing/0001641172-25-017478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/0001641172-25-017478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:34:48.062728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6774d0877d9cd68ea52066dee6a096648b97cfa7","claim":"Sonnet BioTherapeutics Holdings, Inc. incurred convertible notes of $2.0 million with certain accredited investors at no interest maturing June 30, 2026.","evidence_excerpt":"On June 30, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) completed a sale to certain accredited investors of convertible notes in the aggregate principal amount of $2.0 million (the “Convertible Notes”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/0001641172-25-017478-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2.0 million"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Rate","value":"no interest"},{"label":"Maturity","value":"June 30, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}